Abstract

Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.

Original languageEnglish
Pages (from-to)1095-1096
Number of pages2
JournalTrends in Pharmacological Sciences
Volume45
Issue number12
DOIs
StatePublished - Dec 2024

Keywords

  • adaptive immunity
  • checkpoint blockade
  • dendritic cell
  • pancreatic cancer
  • pancreatitis

Fingerprint

Dive into the research topics of 'Targeting dendritic cells to drive PDAC immunotherapy response'. Together they form a unique fingerprint.

Cite this